FOSTER CITY, CA--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced positive topline results from its pivotal Phase 3 MARCH study evaluating LIVMARLI® (maralixibat) oral solution in 93 patients with progressive familial...
Art Pappas will participate on a panel at the C21 BioVentures Conference in Napa, Ca titled "Structured Acquisitions: Win-Win or Lose-Lose?"
News | 04. 08. 2009
